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Themulti-tyrosine kinase inhibitor sunitinib is used in the treatment of several solid tumors.
Animal experiments pointed to an adrenotoxic effect of sunitinib. Therefore, we evaluated
the expression of key targets of sunitinib in human adrenocortical carcinoma (ACC) tumor
samples and investigated its in vitro effects in ACC cell lines. We carried out immuno-
histochemistry for vascular endothelial growth factor (VEGF) and its receptor (VEGF-R2)
in 157 ACC samples and nine normal adrenal glands. VEGF and VEGF-R2 protein were
expressed in 72 and 99% of ACC samples, respectively. Using NCI-H295 and SW13 ACC
cell lines, we investigated the effects of sunitinib on cell proliferation. Sunitinib reduced
dose-dependently cell viability of both NCI-H295 and SW13 cells (SW13: 0.1μM 96± 7%,
1μM 90± 9%*, 5μM 62± 6%*, controls 100± 9%; *p< 0.05). To determine sunitinib
effects on steroidogenesis, we measured steroid hormones in cell culture supernatant
by gas chromatography–mass spectrometry. We observed a pronounced decrease of
cortisol secretion (1μM 90.1± 1.5%*, 5μM 57.2± 0.3%*, controls 100± 2.4%) and a
concomitant increase in the DHEA/4-androstenedione and 17-hydroxypregnenolone/17-
hydroxyprogesterone ratios, indicating speciﬁc inhibition of 3β-hydroxysteroid dehydroge-
nase (HSD3B2). In yeast microsomes transformed with HSD3B2, no direct inhibition of
HSD3B2 by sunitinib was detected. Sunitinib induced down-regulation of HSD3B2 mRNA
and protein in ACC cell lines (mRNA: 1μM 44± 16%*; 5μM 22± 2%*; 10μM 19± 4%*;
protein: 1μM 82± 8%; 5μM 63± 8%*; 10μM 55± 9%*). CYP11B1 was down-regulated
at mRNA but not at protein level and CYP11A1 remained unchanged. In conclusion, target
molecules of sunitinib are expressed in the vast majority of ACC samples. Sunitinib exhibits
anti-proliferative effects in vitro, and appears to speciﬁcally block adrenal steroidogenesis
by down-regulation of HSD3B2, rendering it a promising option for treatment of ACC.
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INTRODUCTION
Sunitinib, a multi-tyrosine kinase inhibitor, has yielded promis-
ing results in a number of tumors that respond poorly to con-
ventional chemotherapy. It is currently used, e.g., as a ﬁrst line
therapy in metastasized renal cancer (Motzer et al., 2007) and
as a second line treatment in advanced gastrointestinal stroma
tumors (Younus et al., 2010). Sunitinib targets several tyrosine
kinase receptors, foremost the vascular endothelial growth factor
receptors 1 and 2 (VEGF-R1 and 2), but also c-KIT, Fms-like tyro-
sine kinase 3 (FLT-3), and platelet derived growth factor receptor
(PDGF-R; Chow and Eckhardt, 2007; Fassnacht et al., 2009). Thus,
the drug combines direct anti-tumor effects with anti-angiogenic
activity.
Adrenocortical carcinoma (ACC) is a rare malignancy with an
annual incidence of about one per million (Golden et al., 2009).
Treatment options are still limited andnew therapeutic approaches
are urgently needed (Libe et al., 2007; Fassnacht et al., 2011). In
one case report, a long lasting response after sunitinib treatment
of ACC has been reported (Lee et al., 2009). We were intrigued by
the fact that sunitinib has been shown to induce adrenal hemor-
rhage in animal experiments (Patyna et al., 2008). Furthermore,
some patients with other solid tumors who received sunitinib dur-
ing phase I–III clinical trials developed impaired responsiveness to
ACTH indicative of adrenal insufﬁciency (Goodman et al., 2007;
Lodish and Stratakis, 2010), which has resulted in a safety note
in the summary of product characteristics (SPC) of sunitinib.
These observations suggest that sunitinibmayhave speciﬁc activity
in ACC.
To further investigate the putative adrenotoxic effects of suni-
tinib we analyzed the expression of the key sunitinib targets VEGF
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and its receptorVEGF-R2 innormal adrenal tissue andACC tumor
samples and tested the effect of sunitinib on cell proliferation
in ACC cell lines. As many ACC patients suffer from tumor
related steroid hormone excess, and with respect to impaired
cortisol secretion in patients treated with sunitinib, we investi-
gated the effects of sunitinib on steroid hormone secretion in the
steroid-producing ACC cell line NCI-H295.
MATERIALS AND METHODS
Sunitinib was provided by Pﬁzer (Karlsruhe, Germany) and dis-
solved in distilled water at pH 7. Forskolin was purchased from
Sigma, Karlsruhe, Germany.
IMMUNOHISTOCHEMISTRY IN ADRENOCORTICAL TUMOR SAMPLES
We collected a total of 195 adrenocortical tissue samples (163
ACC, 23 adenomas, and nine normal adrenal samples) with
informed,written consent by the patients. The study was approved
by the Ethics Committee of the University of Würzburg (#
93/02).
The adrenal tumor samples were assembled into three tis-
sue arrays as described previously (Fenske et al., 2009; Ronchi
et al., 2009). Immunohistochemical detection was performed
using an indirect immunoperoxidase technique after high tem-
perature antigen retrieval in 0.01M citrate buffer (pH 6.0) for
25min. Primary antibodies were VEGF-R2 monoclonal mouse
antibody (Flk-1), used in a dilution of 1:250 and VEGF anti-
body A-20 in a dilution of 1:100 (both antibodies from Santa
Cruz Biotechnology, Heidelberg, Germany). The slides were incu-
bated with the secondary antibody (BioGenex, Neufahrn, Ger-
many) for 20min and washed in PBS followed by the appli-
cation of the chromogen diaminobenzidine. After washing in
PBS and water, the slides were counterstained with hematoxylin.
As negative controls we employed an IgG isotype antibody and
the omission of the primary antibody during immunohisto-
chemical staining. All tissue array slides were analyzed inde-
pendently by two investigators (Dorothee Kühner and Silviu
Sbiera) by assigning staining intensity to the following cate-
gories: negative, low, intermediate, or strong. Where discrepancies
were observed, results were double checked by both investigators
together with a third observer (Martin Fassnacht). Tissue samples
with parts of tumor vessels displayed on the slide were evalu-
ated separately for endothelial VEGF-R2 expression in the same
manner.
ADRENOCORTICAL CELL LINE CULTURE CONDITIONS
NCI-H295ACC cells (Gazdar et al., 1990)were grown asmonolay-
ers in F12 HAM-medium supplemented with insulin, transferrin,
and selenium, 1.2% BSA (Sigma-Aldrich, Deisenhofen, Germany)
and 2.5% fetal calf serum (FCS, PAN Biotech, Aidenbach, Ger-
many). The suspension cell variant of these cells was grown in
RPMI 1640 medium supplemented with transferrin, insulin, sele-
nium, and 5% FCS at 37˚C under an atmosphere of 5% CO2/95%
air as described before (Fassnacht et al., 2002, 2003).
The ACC cell line SW13 (Leibovitz et al., 1973) was cultured in
F15 medium Leibowitz (Sigma-Aldrich) with 10% FCS and 2mM
l-glutamine (Invitrogen, Darmstadt, Germany) under low CO2
conditions (Hahner et al., 2010).
ASSESSMENT OF CELL VIABILITY BY THE DYE EXCLUSION TEST
NCI-H295 ACC cells were plated in six-well-plates at a density
of 5× 105/ml and grown for 2, 4, and 6 days respectively at con-
centrations of 0μM (control), 0.1μM, 1μM, and 5μM sunitinib
(each in triplicate). Aliquots were mixed 1:2 with trypan blue and
cells excluding the dye counted in a Neubauer hemocytometer.
ASSESSMENT OF CELL PROLIFERATION BY MTT ASSAYS
The MTT assay makes use of the conversion of color-less MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide]
into a blue formazan dye in vital cells only. Dye formation as mea-
sured by absorbance at 570 nm hence is a function of viable cell
number (Mosmann, 1983).
Adherent NCI-H295 and SW13 cells were plated into 96-well-
plates, grown over night and exposed to 0μM (control), 0.1, 1,
2, 5, and 10μM sunitinib for 5 days. Culture supernatants were
removed and cells washed with PBS. MTT was dissolved in serum
free DMEM F10 (0.5mg/ml) and cells incubated for 4 h at 37˚C.
Formazan dye was dissolved using 0.04N HCl/2-propanol and
extinction was measured in an ELISA Reader at 570 nm (Fassnacht
et al., 2002).
HORMONE ANALYSIS
Cortisol and DHEA-S were measured in cell culture supernatant
using an Immulite 2000 analyzer (Siemens Medical Solutions,
Bad Nauheim, Germany). 17-hydroxyprogesterone (17OHP) and
4-androstenedione were measured with commercially available
radioimmunoassay (Beckman-Coulter, Krefeld, Germany and
Siemens Medical Solutions).
In addition,4-androstenedione,cortisol,DHEA,11-deoxycortisol,
17-hydroxypregnenolone (17OHPreg),and17-hydroxyprogesterone
(17OHP)weredeterminedby isotopedilutiongas chromatography–
mass spectrometry (GC–MS) as described elsewhere (Wudy et al.,
2001; Wudy and Hartmann, 2004). Brieﬂy, cell supernatant was
equilibrated with internal standard (deuterium-labeled analogs
of analytes). After solvent extraction and puriﬁcation, heptaﬂu-
orobutyrate derivatives were prepared. Gas chromatography was
carried out on an Agilent 6890 series gas chromatograph hous-
ing an OV-1 fused silica capillary (25m× 0.2mm, ﬁlm 0.1μm;
Macherey-Nagel, Düren, Germany) coupled with an Agilent 5973
mass selective detector operated in the selected ion monitoring
mode. For computerized quantiﬁcation, peak areas of speciﬁc
ions of analytes and their corresponding internal standards were
recorded.
HSD3B2 YEAST MICROSOMAL EXPRESSION ASSAY
Enzyme inhibition experiments were conducted as described pre-
viously (Auchus et al., 1998; Arlt et al., 2004). Brieﬂy, yeast micro-
somes transformed with human wild-type HSD3B2 cDNA were
incubated in 50mM potassium phosphate buffer pH 7.4 contain-
ing pregnenolone (10μM), sodium pyruvate (5mM), and lac-
tate dehydrogenase (2 IU/ml). [3H]-pregnenolone (55.4 Ci/mol;
10,000 cpm)was added in 4μl ethanol to a total reaction volumeof
200μl. For inhibition studies, sunitinib (0–5μM) was added and
catalysis initiated by the addition of NAD+ (1mM), with subse-
quent incubation at 37˚C for 30min which had been previously
determined as within the linear range of the enzymatic reaction.
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Steroids were extracted with 2ml dichloromethane, concentrated
by evaporation at 55˚C, and separated by thin layer chromatog-
raphy on PE SIL G/UV silica gel plates (Whatman, Maidstone,
UK), using a 1:4 dichloromethane/ethyl acetate solvent system.
The HSD3B2 substrate pregnenolone and the conversion product
progesterone were quantiﬁed using a Bioscan 2000 image analyzer
(LabLogic, Shefﬁeld, UK).
RNA EXTRACTION, cDNA SYNTHESIS, AND qRT-PCR
RNA was extracted from cultured cells using the respective RNeasy
Kit (Qiagen, Hilden, Germany) according to manufacturer’s man-
ual. Reverse transcription was performed using 500 ng RNA with
QuantiTect reverse transcription kit (Qiagen) employing a mix-
ture of random and oligo-dT primers. qRT-PCR was carried
out using TaqMan Gene Expression Master Mix (Applied Biosys-
tems, Darmstadt, Germany) and expression normalized to β-actin
using the ΔΔC t-method. mRNA of β-actin was demonstrated
to be expressed at similar levels in NCI-H295 and SW13 cells
(C t-values 22.35± 0.19 for NCI-H295 vs. 22.14± 0.023 in SW13,
n = 3, p = 0.12 for difference in unpaired Student’s t -test) and
hence chosen as reference gene. β-actin primer sequences were:
5′-tct aca atg agc tgc gtg tg-3′ (forward), 5′-cag agg cgt aca ggg
ata gc-3′ (reverse). For the target transcripts, commercial probes
from Applied Biosystems were used (HSD3B2: HS00605123_M1,
CYP11B1: HS01596404_M1, CYP11A1: HS00167984_M1).
IMMUNOBLOT ANALYSIS
A number of 106 cells were lysed directly in 100μl SDS-sample
buffer by heating to 96˚C. Samples were then separated on a
discontinuous SDS-PAGE with 5% stacking gel and 10% sep-
aration gel in a Mini Protean II chamber (Bio-Rad, Munich,
Germany). Blotting was done onto Hybond ECL nitrocellulose
membrane (GE Healthcare, Munich, Germany) which was then
blocked with 5% skim milk powder and 0.1% Tween 20 in Tris
buffered saline pH 8.0. Primary polyclonal rabbit antibody against
HSD3B2 (R1484) was a generous gift from Ian Mason, Edin-
burgh and used in a dilution of 1:2500 (Thomas et al., 2002).
CYP11B1 antibodywas obtained fromHiroshi Takemori,National
Institute of Biomedical Innovation, Osaka, Japan (Nonaka et al.,
1995) and employed diluted 1:1000. Secondary antibody was
anti-rabbit IgG conjugated to horse radish peroxidase (HRP)
from GE Healthcare diluted 1:1000. Chemoluminescence reaction
was initiated by adding ECL Western Blotting Detection System
reagent (GE Healthcare) reagent. The membrane was exposed
for 1–5 s to Fuji Medical X-ray ﬁlm and developed automati-
cally. Quantiﬁcation of the optical density was performed after
digital capturing with BioDocAnalyze (Biometra,Göttingen,Ger-
many) using the shareware program JImage (NIH, Bethesda, MD,
USA) and normalized to β-actin staining as a loading control
(anti-β-actin: Sigma A5441, anti-mouse IgG HRP-conjugate, GE
Healthcare).
STATISTICAL ANALYSIS
All assays were performed in at least three independent triplicate
experiments. Data are presented asmeans± SD.One-wayANOVA
with Tukey’s post hoc test was done using GraphPad Prism ver-
sion 3.00 forWindows (GraphPad Software, San Diego,CA,USA).
Figures show one representative experiment.
RESULTS
VEGF AND VEGF-R2 TISSUE ARRAY EXPRESSION ANALYSIS
Utilizing a tissue array we examined the protein expression of
VEGF andVEGF-R2 by immunohistochemistry (Figure 1). VEGF
expression was strong, intermediate, and low in 11, 45, and
57, respectively of 157 evaluable ACC samples while no expres-
sion was detected in 44 of 157 (28%) samples. Seven of nine
normal adrenal glands showed low VEGF protein expression
while in the two remaining samples no speciﬁc staining was
visible.
VEGF-R2 protein expression was strong in 40, intermediate in
74, low in 35, and absent in 2 of 151 evaluable samples. 113 tumor
samples were evaluable for endothelial staining. Strong, interme-
diate, and low VEGF-R2 staining was found in the endothelium
of 9, 68, and 21, respectively, whereas 15 samples (13%) did not
stain for VEGF-R2. In the nine normal adrenal gland samples we
found intermediate (n = 1), low (n = 7), or absent (n = 1) VEGF-
R2 expression. Taken together, expression levels of VEGF and
VEGF-R2 proteins are generally higher in ACC than in normal
adrenal glands.
INHIBITION OF ACC CELL PROLIFERATION BY SUNITINIB
In order to determine the effect of sunitinib on in vitro
proliferation of ACC cells, we ﬁrst performed dye exclusion assays
of NCI-H295 cells. A moderate, dose-dependent inhibition of cell
proliferation was observed at sunitinib treatment (Figure 2A).
Independently, dose-dependent inhibition of proliferation by
sunitinib was conﬁrmed by employing MTT testing in NCI-H295
and SW13 cells (Figure 2B).
FIGURE 1 | Immunohistochemistry ofVEGF andVEGF-R2 in normal
adrenal glands and ACC. (A) An example of a normal adrenal gland (zona
fasciculata, dashed line) with low VEGF expression. Approximately 30% of
ACC exhibit intermediate [(B), borders of VEGF-immunoreactivity dashed],
or strong VEGF staining. VEGF-R2 is expressed in the cortex of normal
adrenal gland but not in the medulla [(C), border of cortex with dashed line].
ACC frequently express high levels of VEGF-R2 in the tumor cells as well as
in the endothelial cells (arrows) as shown in (D). The magniﬁcation in all
images is 400×.
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FIGURE 2 | Sunitinib inhibits proliferation of ACC cell lines in a
dose-dependent manner. (A) NCI-H295 cells were counted after 2, 4, and
6 days of incubation with up to 5μM sunitinib. After 2 days of incubation, we
observed a dose-dependent reduction of viable cells to 99.6±7.5% (0.1μM
sunitinib, n.s.), 84±6% (1μM, n.s.), 66±10%* (5μM) as compared to
untreated control incubations (100±5.2%). (B) After 5 days of incubation,
viable cells were determined using the MTT assay. Viable NCI-H295 cells
were reduced to 98±8% (0.1μM, n.s.), 91±4%** (1μM), and 80±3%**
(5μM) compared to controls (100±8%). Similarly, SW13 vital cells declined
to 96±7% (0.1μM), 90.0±9.2%** (1μM), and 62±6%** (5μM)
compared to control (100±9%). *p<0.05, **p<0.01 compared to control.
SUNITINIB AFFECTS STEROIDOGENESIS
To test whether sunitinib impacts on steroidogenesis in ACC cell
lines, we analyzed steroid concentrations in cell culture super-
natants. To account for the cytotoxic effect described, results
were normalized for cell numbers. Of note, cortisol changed as a
function of sunitinib concentration to 103 ± 10% (0.1μM, n.s.),
96± 7% (1μM, n.s.), 73± 15% (5μM, p< 0.05) compared to
untreated controls (100± 6%) after 4 days of incubation. Con-
versely, DHEA-S increased to 110± 10% (0.1μM), 156± 14%
(1μM), 189± 426% (5μM, p< 0.01) as compared to untreated
cells (100± 12%).
Next we asked whether these changes could be overcome by
stimulation of steroidogenesis with the activator of adenylate
cyclase forskolin (FSK, Figure 3). Three days of simultaneous
incubation with 10μM FSK led to a nearly 2.5-fold increase of
FIGURE 3 | Sunitinib specifically alters basal and forskolin (FSK)
stimulated steroidogenesis in NCI-H295 cells. Cortisol and androgen
precursor secretion was assessed in cell culture supernatants of NCI-H295
cells after 3 days of incubation with sunitinib and/or FSK employing
immunoassays. Representative data from one triplicate experiment are
shown. 10μM FSK led to an increase of cortisol secretion to 247.1±18.3%
compared to control (100±9%, p<0.01). Stimulation of androgen and
precursor steroid secretion was statistically not signiﬁcant (DHEA-S
116±8%, control 100±6%; 17OHP 125±8%, control 100±12%;
4-androstenedione 139±41%, control 100±18%). Co-incubation with
10μM FSK and 5μM sunitinib nearly completely reversed FSK-induced
stimulation of cortisol secretion to 115±18%** of unstimulated cells
whereas production of precursor steroids and androgens was strongly
increased (DHEA-S 238.8±26.8%**, 17OHP 168±12%**,
4-androstenedione 222±10%*). *p<0.05, **p<0.01 compared to FSK
alone.
cortisol secretion compared to control, whereas stimulation of
androgen/precursor secretion was statistically not signiﬁcant. The
addition of 5μM sunitinib decreased cortisol close to baseline
concentrations of unstimulated cells. In contrast, production of
precursor steroids and androgens was strongly increased. Hence
we concluded that sunitinib leads to a speciﬁc inhibition of corti-
sol synthesis and accumulation of androgens and their precursors
also after stimulation of steroidogenesis by FSK.
To assess steroid hormone production more comprehensively
we next conducted isotope dilution GC–MS proﬁling of cell cul-
ture supernatants with and without sunitinib (Figure 4A). In
line with our previous results obtained with immunoassays, cor-
tisol concentration exhibited a strong dose-dependent decrease.
DHEA was found to be strongly enriched and we likewise noted a
moderate increase in 4-androstenedione and 17OHP. In contrast,
deoxycortisol, 17OHP, and testosterone remained unchanged.
From these data, we calculated substrate/product ratios
in order to deﬁne enzyme activities affected by sunitinib
(Figure 4B). We found that the ratios DHEA/4-androstenedione,
17OHPreg/17OHP, and deoxycortisol/cortisol were signiﬁcantly
increased, pointing to speciﬁc inhibition of the steroidogenic
enzymes 3β-hydroxysteroid dehydrogenase (HSD3B2) and 11β-
hydroxylase (CYP11B1). Importantly, the ratios 17OHPreg/DHEA
and 17OHP/4-androstenedione indicative of CYP17 activity were
not altered.
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FIGURE 4 | Sunitinib leads to characteristic changes in steroid profiles.
(A) Isotope dilution GC–MS was used to study changes in steroid proﬁles of
NCI-H295 cell culture supernatants after incubation with sunitinib for 4 days.
Individual values were normalized to control cells (100%). Cortisol
concentration was diminished to 98±2%** (0.1μM), 90±2%** (1μM), and
57±0.3%** (5μM) of control (100±2%) but DHEA increased to 105±6%,
143±7%*, and 170±8%* respectively compared to control incubations
(100.0±3.9%). However, a less pronounced increase was found for
4-androstenedione to 103±2%**, 111±1%**, and 113±2%**
(4-androstenedione, control 100±3%) and for 17OHPreg to 94±2% (n.s.),
123.3±13.7%* (1μM), and 145.4±3.0%** (5μM). (B) Steroid ratios were
calculated for four characteristic substrates and products of HSD3B
(3β-hydroxylase), CYP17 (17,20-lyase), and CYP11B1 (11β-hydroxylase).
*p<0.05, **p<0.01 compared to control.
REGULATION OF HSD3B2 AND CYP11B1 BY SUNITINIB
In order to investigate whether sunitinib directly inhibitsHSD3B2,
we used isolated yeast microsomes transformed with human
HSD3B2. Sunitinib did not exhibit any signiﬁcant inhibition
of HSD3B2 activity across the concentration range of 1–5 μM
sunitinib in these enzymatic assays: 100± 6% (0μM), 99± 2%
(1μM), 94± 2% (5μM).
We therefore hypothesized that sunitinib may alter enzyme
activities at the transcriptional level. Using quantitative PCR, we
investigated the expression of HSD3B2, CYP11B1 (P450c11), and
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FIGURE 5 | Sunitinib leads to reduced mRNA expression of HSD3B and
CYP11B1. (A) CYP11B1 mRNA expression in NCI-H295 cells was
investigated using quantitative PCR using β-actin as a standard.We
observed a dose-dependent reduction to 78.6±12.7% (1μM), 61±3%*
(5μM), and 48±7%** (10μM) compared to control (100±18%). (B)
HSD3B2 mRNA was demonstrated to be down-regulated to 47±7%**
(1μM), 33±7%** (5μM), 27±6%** (10μM, control: 100±27; p<0.01).
*p<0.05, **p<0.01 compared to control.
CYP11A1 (P450scc) mRNA in NCI-H295 cells treated with suni-
tinib.Whereas no change in expression was observed for CYP11A1
(data not shown),we found amoderate dose-dependent reduction
in CYP11B1 after 24 h of incubation compared to control cells
(Figure 5A). Interestingly, HSD3B2 mRNA (Figure 5B) exhib-
ited an even more pronounced down-regulation on the mRNA
level.
To further investigate this ﬁnding, we conducted immunoblot
analysis in sunitinib-treated NCI-H295 cells. Here, we found a
similar sunitinib-induced decrease in HSD3B2 protein expres-
sion compared to control (Figure 6). However, we did not detect
signiﬁcant changes of CYP11B1 protein expression (data not
shown).
DISCUSSION
Here we provide evidence for expression of target mole-
cules of sunitinib in ACC samples and demonstrate a direct
FIGURE 6 | Sunitinib down-regulates HSD3B2 expression at protein
level. (A) HSD3B2 protein expression in NCI-H295 cells after 24 h of
incubation with sunitinib was assessed by immunoblot analysis using a
speciﬁc antibody. (B) Densitometric quantiﬁcation of immunoblot signals
from three experiments conﬁrmed a signiﬁcant sunitinib-induced decrease
of HSD3B2 to 82±8% (1μM, n.s.), 63±8%** (5μM), and 54.6±8.8%**
(10μM) compared to control cells (100±6%). **p<0.01 compared to
control.
anti-proliferative effect of sunitinib on ACC cell lines NCI-H295
and SW13. In addition,we show speciﬁc inhibition of cortisol syn-
thesis and concomitant accumulation of steroid precursors and
androgens caused by down-regulation of HSD3B2 in hormonally
active NCI-H295 cells.
We found low expression of VEGF and its receptor in nor-
mal adrenal glands whereas 72 and 99% of ACC samples showed
expression of VEGF and VEGF-R2, respectively, with 36 and
75% of ACC specimens exhibiting strong or intermediate stain-
ing intensity. Of note, both endothelial cells and ACC tumor
cells expressed VEGF-R2 in a large proportion of specimens.
VEGF expression in both tumor cells and tumor vessels has
been reported in one case before (Lee et al., 2009). Our ﬁnd-
ings indicate that VEGF and VEGF-R2 are up-regulated at protein
level in a signiﬁcant proportion of ACC compared to normal
adrenal glands. In addition, expression of VEGF-R2 has been
demonstrated in SW13 and NCI-H295 cells by immunoblot-
ting (Mariniello et al., 2011). The expression of one of the
key targets of sunitinib, VEGF-R2 and its ligand VEGF in
ACC makes sunitinib a candidate molecule for further clinical
investigation.
In both dye exclusion assays and MTT tests, sunitinib incu-
bation resulted in a dose dependent, moderate but signiﬁcant
decrease of cell proliferation. Both assays cannot distinguish
whether this is due to increased cell death or reduced cell
proliferation. However, these data demonstrate a direct cytostatic
effect of the drug on ACC cells, which is similar to those observed
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in other sunitinib-treated tumor cell lines in vitro (de Boüard
et al., 2007) and which have been reported recently in ACC-cells
with sorafenib (Mariniello et al., 2011). However, in vivo, sunitinib
might affect ACC tumor growth more effectively by also targeting
tumor-associated angiogenesis.
Using immunoassays and GC–MS, we found a speciﬁc effect
of sunitinib on steroidogenesis, with a signiﬁcant decrease of
cortisol whereas 17OHPreg, 4-androstenedione, and DHEA-S
concentrations increased. Furthermore, maximum stimulation of
steroid biosynthesis by protein kinase A (PKA) activation with
forskolin was effectively blocked by sunitinib. Calculation of sub-
strate/product ratios clearly indicated that sunitinib speciﬁcally
reduces HSD3B2 activity, resulting in the observed increase in
androgens and decrease in cortisol. After exclusion of a direct
inhibition of HSD3B2 in a yeast microsome assay, signiﬁcant
down-regulation of HSD3B2 was observed using quantitative
PCR. We conﬁrmed that HSD3B2 was reduced at the protein
level. Altered mRNA stability (Balagopal and Parker, 2009) may
account for HSD3B2 mRNA down-regulation but these processes
have not been investigated in any detail for transcripts involved in
steroidogenesis.
By contrast, transcriptional regulation of HSD3B2 in the
adrenal gland has been studied using a variety of experimental
settings. Key transcription factors include members of the NR5A
(steroidogenic factor 1, SF1 and Liver Receptor Homolog 1, LRH-
1) and the NR4A family (Nur77,Nur related protein 1,Nurr1, and
neuron-derived orphan receptor 1, Nor1; Hammer et al., 2005).
It appears that SF1 accounts for the basal transcriptional activ-
ity of HSD3B2 in NCI-H295 cells and can be stimulated with
phorbol esters indicating a protein kinase C (PKC) dependent
pathway (Leers-Sucheta et al., 1997). Further, it plays a pivotal role
in adrenocortical cell proliferation and cancer (Beuschlein et al.,
2002; Doghman et al., 2007; Lalli, 2010; Sbiera et al., 2010). On
the other hand, Nur77 has been proposed to orchestrate HSD3B2
expression in response to hormonal stimulation via PKA (Bassett
et al., 2004; Martin and Tremblay, 2005).
With respect to upstream pathways, insulin-like growth fac-
tors IGFI and II have been found to stimulate expression of
CYP17 and also HSD3B2 in human adult adrenal fasciculata–
reticularis cells (l’Allemand et al., 1996). Similarly to our obser-
vations, a pharmacologic study demonstrated reduced secretion
of cortisol and increased DHEA and DHEA-S production in
NCI-H295 cells upon inhibition of Src tyrosine kinase with
the speciﬁc inhibitor PP2 (Sirianni et al., 2003). Induction of
steroidogenic acute regulatory protein (StAR),CYP11A1, and 17a-
hydroxylase/17,20-lyase (CYP17 ) were found to mediate these
effects.
Although sunitinib and the Src-inhibitor PP2 ﬁnally lead to
similar changes in steroid production, we did not ﬁnd increased
CYP11A1 expression indicating that the majority of sunitinib
effects is transduced through a different pathway. In fact it is
likely that the observed changes in hormone secretion result
from alterations in more than one signaling pathway taking
into account that VEGF-R2 is only one among several tyrosine
kinases targeted by sunitinib. In addition, cross-talk to PKA and/or
PKC dependent pathways is suggested by the results of forskolin
stimulation.
Our study has obvious limitations: Since only one steroid hor-
mone producing ACC cell line is currently available, we cannot
exclude that the described effect on the steroidogenesis is cell line
speciﬁc and not a general effect of sunitinib. However, NCI-H295
cell line has been ﬁrmly established as a model for hormonally
active ACC (Rainey et al., 1994; Rainey and Nakamura, 2008). In
our in vitro setting, the most pronounced effect was seen using a
sunitinib concentration of 5μM and more. In humans, admin-
istration of 50mg sunitinib per day leads to plasma concentra-
tion of 50–100 ng/ml, corresponding to 0.1–0.2 μM (Faivre et al.,
2006). Thus we administered sunitinib in a presumably “supra-
therapeutical” concentration. In humans, sunitinib is metabolized
in the intestine and liver by CYP3A4 monooxygenase to ﬁrst
form the active metabolite SU12662 which is then inactivated in
a second CYP3A4-mediated step (Faivre et al., 2006). CYP3A4-
mediated inactivation of sunitinib in SW13 and NCI-H295 cells
in vitro is unlikely, since we found no expression of this enzyme
using qRT-PCR (data not shown). However, it is well known that
in vitro much higher concentrations are needed to yield a given
effect compared to the situation in vivo. Accordingly, published
cell culture data for sunitinib support that 0.1–10μM are appro-
priate concentrations to mimic putative in vivo effects (de Boüard
et al., 2007; Salem et al., 2008). Moreover, anti-angiogenic effects
of sunitinib are supposed to enhance the anti-tumoral effects of
the drug in vivo.
From a clinical perspective, our in vitro results support the
possibility of sunitinib-induced adrenal insufﬁciency, primarily
by inhibition of HSD3B2 transcription. Symptoms of adrenal
insufﬁciency such as prostration, stiffness of joints or even gas-
trointestinal disturbances like vomiting and nausea may be easily
attributed to non-speciﬁc side effects of sunitinib or the malignant
disease itself. Although clinically evident adrenal insufﬁciency
appears to be a rare event in patients treatedwith sunitinib (Lodish
and Stratakis, 2010), physicians should be aware that sunitinib
may unmask clinically inapparent adrenal insufﬁciency due to
concomitant treatment with other drugs inﬂuencing steroidogen-
esis (e.g., ketoconazole, ﬂuconazole) or heterozygous congenital
adrenal hyperplasia. On the other hand, glucocorticoid excess
is a hallmark of ACC leading to a high morbidity and in this
situation inhibition of steroidogenesis will be a desired effect.
Taken together, our results indicate that sunitinib may have sig-
niﬁcant therapeutic potential in the treatment of ACC, which
should be explored further in clinical studies, e.g., in the ongo-
ing Sunitinib in refractory adrenocortical carcinoma (SIRAC)
trial.
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